ImmunoPET imaging for pancreatic cancer
Development and Clinical Translation of immunoPET Imaging Probes for Pancreatic Cancer
This study is testing a new imaging method to see how well a targeted therapy for pancreatic cancer gets taken up by tumors and healthy tissues in patients with pancreatic cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | RenJi Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06602037 on ClinicalTrials.gov |
What this trial studies
This study focuses on using ImmunoPET imaging to evaluate the distribution of a targeted therapy for pancreatic cancer. Patients with confirmed or suspected pancreatic cancer will receive a radiolabeled antibody, SHR1920, which will be tracked using PET scans to assess its uptake in tumors and normal tissues. The study aims to determine the diagnostic efficacy of this imaging technique and its correlation with protein expression levels in tumors. By identifying patients who are more likely to benefit from targeted therapies, the study seeks to enhance treatment outcomes for pancreatic cancer.
Who should consider this trial
Good fit: Ideal candidates include individuals with histologically confirmed or suspected pancreatic cancer who can provide informed consent.
Not a fit: Patients with known hypersensitivity to the study agents or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective targeted therapies for patients with pancreatic cancer.
How similar studies have performed: While the use of ImmunoPET imaging is a novel approach in this context, similar imaging techniques have shown promise in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed diagnosis of pancreatic cancer or suspected pancreatic cancer by diagnostic imaging. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion Criteria: * Known or suspected hypersensitivity to SHR1920, DFO/RESCA/NOTA, 89Zr/18F or 68Ga or any of the excipients. * Pregnancy
Where this trial is running
Shanghai
- Renji Hospital, School of Medicine, Shanghai Jiao Tong University — Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Weijun Wei, Ph.D. & M.D. — Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
- Study coordinator: Weijun Wei, Ph.D. & M.D.
- Email: wwei@shsmu.edu.cn
- Phone: 15000083153
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.